Design and Synthesis of Novel β-catenin/BCL9 Protein–Protein Interaction Small Molecule Inhibitors for the Treatment of Colorectal Cancer
Pharmaceutical Fronts · 01.06.2026 · 08 (02) · e129-e141
DOI: 10.1055/a-2834-4404 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.06.2026. Verfasst von Yuyan Long und 2 weiteren Autor:innen.
Abstract (Originalsprache)
AbstractColorectal cancer (CRC) is one of the most common gastrointestinal malignancies. The development of novel targeted drug therapeutics against CRC has been a research hotspot. Among these strategies, disrupting the β-catenin/BCL9 protein–protein interaction (PPI) emerges as a promising approach for the treatment of CRC driven by aberrant Wnt signaling. Currently, most β-catenin/BCL9 PPI inhibitors are peptide-based; however, their intrinsic limitations have hindered further development. Among small-molecule inhibitors, phenylpiperidine derivatives have progressed rapidly. In this study, based on the phenylpiperidine scaffold, we designed and synthesized a series of compounds (A1–A20). Their activities as β-catenin/BCL9 PPI inhibitors were preliminarily evaluated through antiproliferative assays on CRC cells and competitive fluorescence polarization assays. Among these compounds, methyl 2-(4-((4'-isopropyl-[1,1'-biphenyl]-4-carboxamido)methyl)phenoxy)-2-methylpropanoate (A3) showed selective inhibition of the proliferation of Wnt-dependent CRC cells and showed the inhibitory potency against the β-catenin/BCL9 interaction. Molecular docking confirmed that A3 fits well into the β-catenin binding pocket, forming key interactions consistent with the lead compound. These results identify A3 as a promising lead for anti-CRC activity.
Zitieren
APA
Long, Y., Wang, M., & Zhang, Q. (2026). Design and Synthesis of Novel β-catenin/BCL9 Protein–Protein Interaction Small Molecule Inhibitors for the Treatment of Colorectal Cancer. Pharmaceutical Fronts, 08(02), e129-e141. https://doi.org/10.1055/a-2834-4404
Vancouver
Long Y, Wang M, Zhang Q. Design and Synthesis of Novel β-catenin/BCL9 Protein–Protein Interaction Small Molecule Inhibitors for the Treatment of Colorectal Cancer. Pharmaceutical Fronts. 2026;08(02):e129-e141. doi:10.1055/a-2834-4404
BibTeX
@article{Long2026,
author = {Long, Yuyan and Wang, Mengfei and Zhang, Qingwei},
title = {Design and Synthesis of Novel β-catenin/BCL9 Protein–Protein Interaction Small Molecule Inhibitors for the Treatment of Colorectal Cancer},
journal = {Pharmaceutical Fronts},
year = {2026},
volume = {08},
number = {02},
pages = {e129--e141},
doi = {10.1055/a-2834-4404}
}
EUVIMED